AREVA NP SAS

Their core work

AREVA NP SAS (now operating as Framatome) is a major French nuclear technology company that designs, manufactures, and services components and fuel assemblies for nuclear power plants. In H2020, they contributed industrial-scale expertise on reactor safety assessment, advanced fuel development for research reactors, and Generation IV reactor design — particularly sodium-cooled fast reactors. Their role across projects reflects a large industrial player providing real-world operational data, safety validation capabilities, and engineering know-how to European nuclear research consortia.

What they specialise in

How they've shifted over time

AREVA NP's H2020 participation spans 2015–2017 start dates with projects running through 2022. The earlier projects (2015 starts) focused on research reactor fuel conversion and conventional reactor lifetime extension — bread-and-butter topics for a nuclear fuel and components manufacturer. The later wave (2017 starts) shifted toward Generation IV reactor safety, advanced probabilistic risk methods, and multi-hazard frameworks, reflecting the industry's pivot toward next-generation designs and post-Fukushima safety reassessment.

Moving from conventional reactor support toward next-generation reactor safety validation and advanced probabilistic risk methods — aligning with Europe's renewed interest in nuclear as a low-carbon energy source.

How they like to work

AREVA NP never coordinated an H2020 project, consistently joining as a participant or third party — typical for a large industrial company that contributes proprietary data and engineering expertise rather than managing academic consortia. With 69 unique partners across 19 countries, they operate as a widely connected but selective contributor. Their small per-project funding (often under EUR 50K) compared to their HERACLES-CP involvement (EUR 1.87M) suggests they calibrate their commitment based on strategic relevance to their core business.

Broad European network spanning 69 partners in 19 countries, reflecting AREVA NP's position as a go-to industrial partner for nuclear safety and fuel research consortia across the EU.

What sets them apart

AREVA NP brings something most academic partners cannot: real operational data from commercial nuclear plants and fuel manufacturing facilities. They bridge the gap between laboratory research and industrial deployment, making them invaluable for projects that need to validate results against actual reactor conditions. For consortium builders, partnering with AREVA NP signals industrial relevance and provides a credible pathway from research to application in the nuclear sector.

Highlights from their portfolio

• HERACLES-CP
  By far their largest H2020 investment (EUR 1.87M) — focused on converting European high-performance research reactors from high to low-enriched uranium fuel, a strategic non-proliferation priority.
• ESFR-SMART
  Positions AREVA NP in the Generation IV sodium fast reactor space — a forward-looking bet on next-generation nuclear technology with strong European policy backing.
• NARSIS
  Addresses post-Fukushima multi-hazard risk assessment for nuclear plants using advanced probabilistic methods — a topic with growing regulatory urgency worldwide.